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Pulmonary blastoma: a comprehensive overview of a rare entity
Abstract
Introduction: Pulmonary blastoma is a rare malignancy, accounting for less than 0.5% of primary lung tumors. It belongs to the 
group of pulmonary sarcomatoid carcinomas, and it is typically characterized by a biphasic pattern of an epithelial and a mes-
enchymal component. Only a few hundred cases have been reported worldwide. The aim of this study is to review and critically 
assess the literature regarding pulmonary blastoma.
Material and methods: A narrative literature review of PubMed database from the inception of the database up to January 2021, 
limited to the English language, was conducted, using combinations of the following keywords: “pulmonary blastoma”, “biphasic 
pulmonary blastoma”, “sarcomatoid carcinoma”.
Results: Pulmonary blastoma is composed of an epithelial and a mesenchymal malignant component. Regarding pathogenesis, 
the origin of the biphasic cell population remains elusive. Characteristic immunohistochemical stains are supportive of diagno-
sis. Clinically, the symptomatology is non-specific, while 40% of the cases are asymptomatic. It is diagnosed at a younger age 
compared to other types of lung cancer, and it is often non-metastatic at diagnosis allowing for surgical treatment. Data on 
management and survival are scarce and mainly come from isolated cases. Advances on targeted therapy may provide novel 
treatment options. Given the rarity of the cases, multicenter collaboration is needed in order to establish therapeutic guidelines.
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Introduction
Pulmonary blastoma (PB) is a rare malignan-
cy that is estimated to account for 0.25 to 0.5% 
of all pulmonary neoplasms. It was seminally 
described in 1945 by Barrett and Barnard and 
was referred to as “embryoma”; however, in 1961, 
Spencer termed the tumor “blastoma” due to its 
histologic resemblance to the fetal lung at the 
10–16-week stage of development (paraadenomal 
stage of lung development) [1]. Koss et al. (1991) 
classified pulmonary blastoma into 3 different 
subtypes: a) classic biphasic pulmonary blasto-
ma (CBPB), b) pleuropulmonary blastoma (PPB) 
and c) well-differentiated fetal adenocarcinoma 
(WDFA) [2]. Pleuropulmonary blastoma pre-
dominantly presents in children and represents 
the most common primary pediatric pulmonary 
malignancy [3]. Classic biphasic pulmonary 
blastoma is typically characterized by a biphasic 
pattern consisting of a primitive mesenchymal 
stroma along with an epithelial component of 
fetal adenocarcinoma, while well-differentiated 
fetal adenocarcinoma is a monophasic tumor, 
presenting with immature adenocarcinoma as 
histologic characteristics [2]. Of note, since 
the WHO classification of lung tumors in 1999, 
pleuropulmonary blastoma is grouped with mes-
enchymal tumors, while fetal adenocarcinoma is 
classified as a subtype of lung adenocarcinoma 
[4]. Pulmonary blastoma is separately categorized 
as a type of sarcomatoid carcinoma of the lung 
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[4, 5]. No significant changes have been made in 
the following versions, and therefore, the same 
terminology and categorization are adopted in the 
current WHO classification of lung tumors [6].
Only a few hundred cases of PB have been 
reported in the literature worldwide [7, 8]. Data 
on pathogenesis, epidemiology, management, and 
survival of pulmonary blastoma is scarce, and 
most evidence comes from case reports and case 
series. Additionally, the changes in the nomencla-
ture of the tumor have led to confusion regarding 
the interpretation of earlier studies. Recently, the 
interest in rare pulmonary tumors has increased 
regarding both the pathogenetic and the clinical 
perspectives. To this end, the aim of this narrative 
review is to summarize updated data on patho-
genesis, epidemiology, management, and outcome 
of pulmonary blastoma.
Pathogenesis
As far as the etiology is concerned, a cor-
relation with smoking has been proposed with 
some cases demonstrating p53 mutation [9, 10]. 
Mutations in the gene of b-catenin have also been 
detected, similarly to other blastomas occurring 
in extrapulmonary sites, and those mutations 
are associated with the formation of morules in 
the tissue [11, 12]. Beta-catenin presents with 
a characteristic pattern of nuclear accumulation, 
which is unveiled with immunohistochemistry 
[11]. Of note, the mutations in b-catenin indicate 
a possible implication of the Wnt signaling path-
way in the pathogenesis of PB [11]. In addition, 
a pathologic and molecular analysis of sixteen 
cases of PB demonstrated mutations in nine can-
cer-associated genes, namely BRCA2, ERBB4, ALK, 
MET, BRAF, RAF1, PTEN, EGFR, and PIK3CA [7].
PB belongs to the group of pulmonary sar-
comatoid carcinomas, which are poorly differ-
entiated non-small cell lung cancers (NSCLC), 
including a part of sarcoma-like elements or true 
sarcomatous areas [5, 6].  An interesting question 
regarding the pathogenesis of sarcomatoid carci-
nomas is whether the biphasic population of cells 
derives from a single ancestor cell or not. Two 
hypotheses have been proposed; the convergent 
hypothesis, suggesting that the different cancer 
cell types arise from different stem cells of epi-
thelial and mesenchymal origin, and the diver-
gent hypothesis proposing a single totipotential 
stem cell origin [13]. Moreover, the pathogenesis 
of sarcomatoid carcinomas has gained interest 
due to the potential involvement of the epithe-
lial-mesenchymal transition (EMT) resulting in 
the formation of a mesenchymal component in 
an otherwise epithelial tumor [5]. Regarding pul-
monary blastoma, evidence supportive of a single 
cell origin has been derived from genetic studies 
[11, 14]. Additionally, a study exploring whole-ge-
nome allelic imbalance in a case of pulmonary 
blastoma demonstrated common alterations in 
both epithelial and mesenchymal components 
of the tumor [15].
Histology
Histologically, the tumor is composed of 
an epithelial and a mesenchymal component 
(Figure 1A, B). The epithelial element is morpho-
logically characterized by irregularly branching 
glandular structures, lined by pseudostratified 
columnar cells with clear cytoplasm and little 
nuclear atypia. The appearance is similar to the 
gestational lung in the pseudoglandular phase 
[2]. An embryonic stroma with oval cells with 
a high nuclear-to-cytoplasmic ratio is present, 
but up to one-quarter of the cases contain foci of 
osteosarcoma, chondrosarcoma, and rhabdomyo-
sarcoma [5]. Areas of necrosis and hemorrhage 
are commonly observed within the tumor [2]. 
Tissue sampling from multiple areas is essen-
tial to confirm the presence of both epithelial 
and mesenchymal malignant components and 
establish the diagnosis [16]. Formally, a definite 
diagnosis is not possible based on small biopsy 
or cytology specimens because it requires a sar-
comatoid/sarcomatous component in at least 10% 
of the neoplasm. However, a diagnosis of “NSCLC 
with sarcomatoid/sarcomatous component, pos-
sible sarcomatoid carcinoma” is reasonable [6].
Due to diagnostic dilemmas, immunohisto-
chemistry is largely used, and it is supportive in 
reaching the diagnosis of PB. On the one hand, 
epithelial components stain positive for Cytoker-
atin, CEA, epithelial membrane antigen (EMA), 
thyroid transcription factor-1 (TTF-1), and surface 
protein alpha [17]. On the other hand, the stromal 
components stain positive for vimentin, desmin, 
muscle-specific actin, myoglobin, and S-100 [14, 
18–20]. It has been proposed that b-catenin accu-
mulation in the nucleus could be used as an ad-
ditional criterion for the diagnosis of pulmonary 
blastoma [21] (Figure 1C, D).
Clinical and radiographic characteristics
PB has both a local growth pattern invading 
adjacent structures and a hematogenous met-
astatic spread. The most common symptoms 
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that occur are cough, hemoptysis, shortness of 
breath, recurrent pneumonia, fever, and weight 
loss, but asymptomatic tumors, accounting for 
40% of cases, may also be detected incidentally 
[22–25]. There is a similarity in the anatomical 
presentation of these tumors. Involvement of the 
upper lobes, restriction to only one lung, and mean 
tumor size of 7–10cm are some of them [8, 26–28]. 
Hematogeneous metastases in the brain, bones, 
and liver, similar to NSCLC, but also in the breast, 
ovaries, peritoneum have been reported [8, 29]. 
There is no established biomarker indicating the 
diagnosis of PB, however, alpha-fetoprotein (AFP) 
increase has been identified in a few cases [30, 31].
In computed tomography of the chest, PB is 
characterized by well-circumferenced lesions, 
with dense and vesical elements with varying 
contrast uptake and central necrosis. Invasion of 
the pleura is possible and endobronchial growth 
is present in 25% of cases [16, 22]. The proximity 
to the pleura renders the bronchoscopy and biop-
sy difficult in the majority of the cases. A CT-guid-
ed transthoracic biopsy may be more convenient 
for diagnosis [32]. 
Table 1 summarizes typical histologic, im-
munohistochemical, clinical, and radiographic 
characteristics of pulmonary blastoma. 
Epidemiology 
Pulmonary blastoma is typically diagnosed 
at a younger age compared to NSCLC, as the 
majority of the patients are diagnosed before 
50 years old [33–59]. A bimodal age distribution 
with peaks of incidence in the 4th and 7th decade 
of life has been reported [18], however, this has 
not been confirmed in a recent epidemiological 
study [60]. Regarding the gender predilection of 
the neoplasm, the results are ambiguous. Some 
studies report a male predominance [18, 40, 61], 
while others describe equal prevalence or even 
predominance of female gender [32, 60].  It should 
Figure 1. Biphasic tumor consisting of areas of fetal adenocarcinoma (A) and a mesenchymal fibroblastic-like cells (B). Both epithelial and mesen-
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be noted that earlier studies may have included 
fetal adenocarcinomas within the term of pulmo-
nary blastoma, which may differ concerning the 
epidemiological features and thus, it needs to be 
considered when interpreting the data [55].
Prognosis of pulmonary blastoma has been 
considered poor, based on the reported survival 
of isolated case reports and case series [2, 39, 29]. 
Nevertheless, in the most recent epidemiological 
study, with data deriving from the Surveillance, 
Epidemiology and End Results (SEER) database of 
the US population, it has been demonstrated that 
nearly half of the PB patients achieved long-term 
survival [60]. In fact, the 5- and 10-year survival 
rates in all PB patients were 58.2 and 48.5% [60]. 
Management and outcome
The majority of the patients with pulmonary 
blastoma are diagnosed at earlier stages, which 
allows for surgical treatment [29]. Similar to NS-
CLC, lobectomy is the most frequent procedure 
performed [8, 27, 47]. A study of 5 patients with 
PB by Liman et al. between 1987 and 2000 re-
ported long-term survival after radical surgery, 
in patients with small size tumors (< 5 cm) with-
out nodal involvement [47]. Specifically, in this 
study, one patient presented with stage T1N0M0, 
one individual with T2N0M0, and three patients 
with T2N1M0. As it was anticipated, the subjects 
without nodal involvement had the most favor-
able outcome [47].
The efficacy of adjuvant therapy has not been 
established with clinical trials; however, several 
published cases are reporting good outcomes with 
the use of adjuvant chemotherapy with or without 
radiotherapy [29, 62, 32]. Cisplatin combined 
with etoposide has been proposed as a regimen 
for adjuvant chemotherapy based on a review 
of the literature [63]. In a more recent report 
by Lewis et al. (2018), two patients underwent 
surgical treatment and they received adjuvant 
cisplatin-based chemotherapy for four cycles 
followed by thoracic radiation. Both patients 
achieved long-term survival [62]. 
Additionally, a few reports have described 
cases in which the patients received neoadjuvant 
therapy for downstaging before surgical resection. 
Bosch-Barrera et al. (2015) reported a 25-year-
old patient with unresectable locally advanced 
pulmonary blastoma who received neoadjuvant 
chemoradiotherapy with two induction cycles of 
cisplatin plus etoposide, followed by concurrent 
weekly cisplatin and radiotherapy treatment. 
The tumor size significantly decreased, allow-
ing for complete resection by pneumonectomy 
[59]. In another case, a 17-year-old male with 
a large tumor (12cm) with adjacent chest wall 
infiltration, which was considered unresectable 
initially, received preoperative chemotherapy 
with cisplatin plus etoposide. The reevaluation 
with chest CT scan after 3 cycles of chemotherapy 
demonstrated good regression of the mass. There-
fore, the man underwent right upper and middle 
lobectomy followed by adjuvant local irradiation 
[57]. Moreover, in a patient who presented disease 
recurrence with a large mass, and although the 
original plan was for definitive radiation thera-
py with concurrent cisplatin and etoposide, the 
tumor regressed considerably after 2 weeks of 
treatment. Therefore, a preoperative course of 
radiation therapy and chemotherapy was decided 
and three weeks after completing therapy, he was 
reassessed with a chest CT showing impressive 
regression of disease, allowing for surgical treat-
ment with right pmeumonectomy [67].
Table 1. Histologic, immunohistochemical, clinical, and radiographic characteristics of pulmonary blastoma
Pulmonary blastoma Characteristics
Pathology Epithelial component: irregularly branching glandular structures, lined by pseudostratified 
columnar cells with clear cytoplasm and little nuclear atypia (fetal adenocarcinoma).
Mesenchymal component:  oval cells with a high nuclear-to- cytoplasmic ratio is present by definition, 
but up to one-quarter of the cases contain foci osteosarcoma, chondrosarcoma, and rhabdomyosarcoma
Immunohistochemistry Epithelial component: Cytokeratin, CEA, epithelial membrane antigen (EMA), 
thyroid transcription factor-1 (TTF-1), and surface protein alpha
Mesenchymal component: stromal components stain positive for vimentin, desmin, 
muscle-specific actin, myoglobin, and S-100
Clinical presentation Cough, hemoptysis, shortness of breath, recurrent pneumonia, fever, and weight loss 
Asymptomatic tumors (40% of cases)
Radiographic presentation Well-circumferenced lesions, with dense and vesical elements 
with varying contrast uptake and central necrosis
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Regarding metastatic disease, treatment 
mainly includes chemotherapy; however, guide-
lines on regimens do not exist. Cutler et al. (1998) 
[63] and more recently Lewis et al. (2018) [62] 
have reviewed reports of patients who received 
chemotherapy. Historically, single-agent chemo-
therapy was initially tried with no clinical or 
objective response [62]. Vila et al. were the first 
to use combination chemotherapy with chloram-
bucil plus methotrexate in 1973 [33]. Over the 
following decades, oncologists applied various 
cytotoxic regimens, namely cisplatin-etoposide 
with or without ifosfamide and cyclophospha-
mide- and vincristine-based regimens. Other che-
motherapeutic drugs that have been commonly 
used are carboplatin, doxorubicin, and paclitaxel 
[34, 52, 58, 65]. Moreover, two reports have been 
published of patients who received sorafenib; 
in one case the patient had a renal metastasis 
which responded well to sorafenib allowing for 
surgical treatment with radical nephrectomy [29, 
50]. Interestingly, other four cases of metastasec-
tomy have been reported, two of them involving 
metastatic tumors in the brain, in one case, a met-
astatic lesion in the breast, and finally, a case of 
metastatic PB to the ovary [48, 34, 62].
Only a few reports exist on the molecular 
alterations detected in PB, and even fewer that 
qualify for targetable therapies. Two cases have 
been published in which the tumor carried 
a ROS1 rearrangement. In the first case, fluores-
cence in situ hybridization (FISH) demonstrated 
a ROS1 rearrangement in 7/50 tumor cells (14%) 
[20]. In the other case, the patient had a detect-
able CD74– ROS1 rearrangement and responded 
to crizotinib, providing a novel option for the 
treatment of PB [66]. The evidence remains 
scarce with regards to other molecular alterations; 
however, in the absence of established therapies 
and given the adenocarcinoma component of 
the tumor, it is reasonable to search for possible 
targetable mutations [26]. Finally, regarding im-
munotherapy, high expression of PD-L1 has been 
reported in some cases of PB, but no study has 
been published yet with the use of an immuno-
therapeutic agent [59]. 
Our literature review of recent (2000–2020) 
cases of patients with pulmonary blastoma who 
received chemotherapy in any setting (neoadju-
vant, adjuvant, or metastatic) is shown in Table 
2 [26, 28–30, 45, 47, 49, 50, 64, 66–71, 52, 54, 
57–59, 62, 72–75]. Only English literature is 
included. Demographics characteristics, che-
motherapeutics regimens, as well as reported 
survival, are summarized in the table.
Conclusion
Pulmonary blastoma is a rare tumor with 
unknown pathogenesis and aggressive behavior. 
It is diagnosed at a relatively young age, and it 
is frequently non-metastatic at diagnosis, allow-
ing for surgical treatment. No guidelines exist 
regarding neoadjuvant or adjuvant therapy and 
concerning the optimal management of metastatic 
tumors. Due to the rarity of the cases, multicenter 
Table 2. Summary of published cases since 2000 of patients with pulmonary blastoma who received chemotherapy and 
kinase inhibitors in any setting (neoadjuvant, adjuvant, or metastatic)
Author Year Age/sex Surgery Chemo or radiation Survival
Bini et al. [67] 2001 53/M LL Lobectomy After recurrence: Chemotherapy 
cisplatin-etoposide × 3 cycles
12 m
Zaidi et al. [68] 2002 24/F LU Lobectomy Neoadjuvant vincristine, dactinomycin, 
ifosfamide, doxorubicin, etoposide, 
carboplatin
Alive at 35 m
Zaidi et al. [68] 2002 23/M No Vincristine, dactinomycin, cyclophos-
phamide, cisplatinum, doxorubicin
8 m
Walker et al. [45] 2005 21/F Thoracotomy with decortication Chemotherapy due to residual disease 
after surgery
6 m
Liman et al. [47] 2006 27/F RU Lobectomy Vincristine and cyclophosphamide 
followed by ifosfamide and etoposide
17 m
Liman et al. [47] 2006 54/M RL Lobectomy Vincristine and cyclophosphamide 10 m
Oshika et al. [49] 2007 58/M RU Lobectomy and mediastinal 
LN dissection
Adjuvant chemotherapy with cisplatin 
and etoposide; Radiation after 
recurrence
Alive 70 m 
postop
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Author Year Age/sex Surgery Chemo or radiation Survival
Mulamalla et al. 
[50]
2007 37/F RU Lobectomy with LN dissection; 
Resection of local recurrence; 
Laparoscopic radical nephrectomy 
after response to sorafenib
Pemetrexed and bevacizumab × 3 in 
combination with radiation (4800 cGy) 
Sorafenib
NA
He et al. [69] 2008 47/F The mass was removed en bloc 




× 3 ;radiotherapy 
3 y postop 
alive- disease 
free
Yu et al. [70] 2009 38/F Lobectomy, metastasectomy 
(abdominal hysterectomy and bilateral 
salpingo-oophorectomy)
Adjuvant radiotherapy and chemothera-
py (cisplatin and etoposide)
NA
Zagar et al. [64] 2010 24/M RU Lobectomy, R pneumonectomy Five years after lobectomy: Neoad-
juvant radiation (60 Gy) followed by 
concurrent chemo-RT with cisplatin and 
etoposide (50 Gy total) in 2 Gy daily 
fractions; followed by adjuvant cisplatin 
and etoposide × 2 cycles
NA
Schwitter et al. 
[71]
2011 28/F LU Lobectomy and LN dissection Adjuvant Chemotherapy (initially ifos-
famide, vincristin, actinomycin D and 
doxorubicin, later ifosmamide/cisplatin) 
Stereotactic Radiosurgery and whole 
brain RT (30 Gy)
Alive at 18 m 
Van Loo et al. [29] 2011 77/M RU Lobectomy with LN dissection After recurrence: Sorafenib 12 m
Lindet et al. [52] 2011 22/F R Pneumonectomy, pericardiectomy After recurrence: 1st line: Ifosfamide, 
doxorubicin × 6 cycles then doxoru-
bicin × 2 cycles followed by stereo-
tactic radiotherapy (40 Gy); 2nd line: 
carboplatin, vincristine, 3rd line: cyclo-
phosphamide; actinomycin-D, 4th line: 
docetaxel/gemcitabine
18 m 
Sharma et al. 
[54]
2013 63/M RL Lobectomy After recurrence: Four cycles of cyclo-
phosphamide, doxorubicin and vincris-
tine (CAV)
NA
Muthu et al. [57] 2014 17/M RU/RM Lobectomy; Tumorectomy 
along with excision of segments 
of fourth and fifth ribs
Neoadjuvant chemo with 3Cy  Cis-VP
Adjuvant RT, declined adjuvant chemo
Declined chemo after 1st recurrence
After 2nd recurrence Æ Cis-VP. The tu-
mor was then de-bulked and its residue 
was irradiated; palliative radiation to 
the spine
24 m
Gallo et al. [72] 2015 43/M No Four cycles of cisplatin, ifosfamide, and 
etoposide (VIP) concurrently with 40 Gy 
external-beam radiation in 20 fractions
NA
Sakata et al. [58] 2015 63/M LU Lobectomy and LN dissection After recurrence: Carboplatin, 




2015 25/F Pneumonectomy (after neoadjuvant} Neoadjuvant chemoradiotherapy based 
on two induction cycles of cisplatin 
plus etoposide, followed by concurrent 
weekly cisplatin to 50.4 Gy 
radiotherapy
Alive 8 m 
postop
Kilic et al. [73] 2016 68/M LUL lobectomy,  Cranial metastectomy After recurrence: Radiotherapy 
and chemotherapy
6 m
Liu et al. [28] 2017 53/M Left lobe resection plus mediastinal 
LN dissection
Adjuvant: Paclitaxel combined 
with nedaplatin × 4
Recurrence: RT 42 Gy/21 f
pemetrexed + cisplatin 
+ bevacizumab
18 m
Table 2. Summary of published cases since 2000 of patients with pulmonary blastoma who received chemotherapy and 
kinase inhibitors in any setting (neoadjuvant, adjuvant, or metastatic)
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Author Year Age/sex Surgery Chemo or radiation Survival
Caer et al. [74] 2018 71/F RL Lobectomy 1st: Cisplatin-vepesid, 2nd: 
Carbo-etoposide; RT; Carbo-etoposide
Alive at 7 y 
postop
Meng et al. [66] 2018 44/F No Crizotinib first time used for PB (CD74–
ROS1 rearrangement) Æ reduction in 
pleural effusion and 34.4% shrinkage of 
tumor size and improvement of symp-
toms, after 3m PD with enlarged L lung 
lesion and L pleural effusion
3 m PFS
Lewis et al. [62] 2018 38/F LU Lobectomy with chest wall resec-
tion and mediastinal LN dissection, 
right parietal craniotomy, gamma knife 
radiosurgery (GKRS)
Adjuvant chemotherapy with cisplatin 
and vinorelbine , thoracic radiation with 
50.4 Gy in 28 fractions.
Alive at 10 y 
postop
Lewis et al. [62] 2018 29/F Thoracotomy and resection of the 
tumor
Resection of the ovarian masses
Cisplatin, ifosfamide, vepesid,
59.49 Gy of radiation in 33 fractions
Alive at 10 y 
postop
Yang et al. [30] 2019 29/F RM Lobectomy with LN dissection Adjuvant Radiotherapy and nedaplatin Alive at 6 m 
postop
Vossler et al. [75] 2019 66/F Left Lobectomy Palliative radiation and chemotherapy 
(cisplatin and etoposide)
6 m 
Luo et al. [26] 2020 58/M RU Lobectomy Adjuvant: Nedaplatin plus paclitaxel 
After recurrence: two cycles of etopo-
side-cisplatin and six cycles of peme-
trexed, bevacizumab, and carboplatin. 
The chemotherapy was stopped due to 
toxicity. The patient was finally admin-
istered anlotinib, a new oral multikinase 
inhibitor
Alive at 4 
years 
F — female; M — male; R — right; L — left; RU — right upper; RM — right middle; RL — right lower; LU — left upper; LL — left lower; m — months; y — years; 
Gy — Grey; NA — not available
Table 2. Summary of published cases since 2000 of patients with pulmonary blastoma who received chemotherapy and 
kinase inhibitors in any setting (neoadjuvant, adjuvant, or metastatic)
collaboration is sorely needed in order to provide 
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